Saturday 17 October 2026
Export NEOG’s income statement to Excel — free account
Neogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025. In the quarter to August 2026, revenue grew 6.51%, EPS fell 132.1%, free cash flow grew 135.8% and total debt fell 2.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.81
0.46
−3.75%
Follow NEOG
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 4 | 4 |
+8 more TTM periods Free account |
| (2.67%) | (0.38%) | (25.56%) | (25.25%) | ||
| (1.68%) | (0.23%) | (16.46%) | (16.26%) | ||
ROIC |
(0.17%) | (0.50%) | (14.53%) | (14.24%) | |
Return on Tangible Assets |
(7.36%) | (1.02%) | (78.93%) | (79.31%) | |
Average Days of Receivables |
56.24 | 61.56 | 57.48 | 54.73 | |
Free Cash Flow per Share |
0.23 | 0.15 | 0.03 | (0.08) | |
Free Cash Flow |
49.85 | 32.00 | 6.30 | (17.87) | |
Capital Expenditures |
(35.40) | (51.20) | (63.10) | (84.02) | |
| Other line items | |||||
Cash ROIC |
1.64% | 1.04% | 0.21% | (0.59%) | |
Accounts Receivable Turnover |
6.44 | 5.80 | 5.86 | 5.95 | |
Accounts Payable Turnover |
6.03 | 5.82 | 6.47 | 6.67 | |
Inventory Turnover |
2.74 | 2.76 | 2.60 | 2.63 | |
Average Days of Payables |
60.91 | 62.51 | 57.54 | 48.38 | |
Days of Inventory on Hand |
114.69 | 114.03 | 123.72 | 124.93 | |
Tax Rate |
(0.17) | (0.12) | (0.03) | (0.02) | |
Research and Development Expense of Revenue |
2.24% | 2.11% | 2.27% | 2.33% | |
Selling, General and Administrative Expense of Revenue |
45.99% | 47.30% | 47.30% | 46.99% | |
Share Based Compensation of Revenue |
1.31% | 1.54% | 1.69% | 2.02% | |
Interest Coverage |
(0.13) | (0.37) | (10.61) | (9.95) | |
Operating CF/Net income |
(1.52) | (10.53) | (0.11) | (0.11) | |
Depreciation/Fixed assets |
0.38 | 0.38 | 2.18 | 2.19 | |
Capex/Depreciation |
(0.28) | (0.41) | (0.09) | (0.12) | |
Revenue per Share |
4.05 | 4.00 | 4.00 | 4.05 | |
Operating CF per Share |
0.39 | 0.38 | 0.32 | 0.30 | |
Capex per Share |
(0.16) | (0.24) | (0.29) | (0.39) | |
Capex to Sales |
0.04 | 0.06 | 0.07 | 0.10 |
Columns are period end dates · fundamentals updated 13 Oct 2026